Clinical trial
A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839…
NCT00238797 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00238797 |
|---|---|
| Title | A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme |
| Official title | A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa™) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Glioblastoma |
| Intervention type | Drug |
| Interventions | Gefitinib |
| Enrollment | 36 |
| Start date | Feb 1, 2003 |
| Completion | Mar 1, 2006 |
| First posted | Oct 14, 2005 |
| Last update posted | Jan 21, 2011 |
| Countries | Sweden |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: